• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医师健康研究中阿司匹林成分提前终止使用的相关问题。医师健康研究数据监测委员会。

Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study.

作者信息

Cairns J, Cohen L, Colton T, DeMets D L, Deykin D, Friedman L, Greenwald P, Hutchison G B, Rosner B

机构信息

Harvard School of Public Health, Boston, MA.

出版信息

Ann Epidemiol. 1991 Aug;1(5):395-405. doi: 10.1016/1047-2797(91)90009-2.

DOI:10.1016/1047-2797(91)90009-2
PMID:1669520
Abstract

The Physicians' Health Study is a randomized, double-blind, placebo-controlled prevention trial of 22,071 US physicians, using a factorial design to evaluate the role of aspirin in the prevention of cardiovascular mortality and beta carotene in the reduction of cancer incidence. After approximately 5 years of follow-up, the aspirin component was terminated, 3 years ahead of schedule. Several factors were considered in the decision to terminate, including a cardiovascular mortality rate markedly lower than expected in both aspirin and placebo subjects, precluding the evaluation of the primary aspirin hypothesis, and a highly significant (P < .00001) and impressive (44%) reduction in the risk of first myocardial infarction in the aspirin group. Issues in the decision to terminate are described in this report.

摘要

医师健康研究是一项针对22071名美国医师的随机、双盲、安慰剂对照预防试验,采用析因设计来评估阿司匹林在预防心血管疾病死亡中的作用以及β-胡萝卜素在降低癌症发病率中的作用。经过约5年的随访,阿司匹林部分提前3年终止。终止该试验的决定考虑了几个因素,包括阿司匹林组和安慰剂组的心血管疾病死亡率均明显低于预期,这使得无法对阿司匹林的主要假设进行评估,以及阿司匹林组首次心肌梗死风险显著降低(P <.00001)且降幅可观(44%)。本报告描述了终止该试验决定过程中的相关问题。

相似文献

1
Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study.医师健康研究中阿司匹林成分提前终止使用的相关问题。医师健康研究数据监测委员会。
Ann Epidemiol. 1991 Aug;1(5):395-405. doi: 10.1016/1047-2797(91)90009-2.
2
Biochemical markers of compliance in the Physicians' Health Study.
Am J Prev Med. 1990 Sep-Oct;6(5):290-4.
3
Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians.
Am J Prev Med. 1991 May-Jun;7(3):150-4.
4
Migraine and subsequent risk of stroke in the Physicians' Health Study.医师健康研究中偏头痛与后续中风风险
Arch Neurol. 1995 Feb;52(2):129-34. doi: 10.1001/archneur.1995.00540260031012.
5
A randomized trial of aspirin and beta-carotene among U.S. physicians.美国医生中阿司匹林和β-胡萝卜素的随机试验。
Prev Med. 1985 Mar;14(2):165-8. doi: 10.1016/0091-7435(85)90031-3.
6
Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.初步报告:正在进行的医生健康研究中阿司匹林成分的研究结果。
N Engl J Med. 1988 Jan 28;318(4):262-4. doi: 10.1056/NEJM198801283180431.
7
Final report on the aspirin component of the ongoing Physicians' Health Study.正在进行的医生健康研究中阿司匹林成分的最终报告。
N Engl J Med. 1989 Jul 20;321(3):129-35. doi: 10.1056/NEJM198907203210301.
8
Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians.美国医生低剂量阿司匹林随机试验中的年龄相关性黄斑病变
Arch Ophthalmol. 2001 Aug;119(8):1143-9. doi: 10.1001/archopht.119.8.1143.
9
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.长期补充β-胡萝卜素对恶性肿瘤和心血管疾病发病率无影响。
N Engl J Med. 1996 May 2;334(18):1145-9. doi: 10.1056/NEJM199605023341801.
10
Estimating the effect of the run-in on the power of the Physicians' Health Study.
Stat Med. 1991 Oct;10(10):1585-93. doi: 10.1002/sim.4780101010.

引用本文的文献

1
Commentary on Wittes et al: Aspirin for primary prevention of CV events - Rationally robust? Statistically significant? Clinically convincing?关于维茨等人的评论:阿司匹林用于心血管事件的一级预防——合理可靠?具有统计学意义?临床说服力强?
Clin Trials. 2025 Aug;22(4):462-465. doi: 10.1177/17407745251324865. Epub 2025 Apr 1.
2
Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions.析因随机试验的方案内容与报告指南:CONSORT 2010和SPIRIT 2013扩展版的解释与阐述
BMJ. 2025 Feb 4;388:e080785. doi: 10.1136/bmj-2024-080785.
3
Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.
用于预防年龄相关性黄斑变性的抗氧化维生素和矿物质补充剂。
Cochrane Database Syst Rev. 2017 Jul 30;7(7):CD000253. doi: 10.1002/14651858.CD000253.pub4.
4
When and how can endpoints be changed after initiation of a randomized clinical trial?在随机临床试验启动后,终点指标何时以及如何能够更改?
PLoS Clin Trials. 2007 Apr 13;2(4):e18. doi: 10.1371/journal.pctr.0020018.
5
Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia.长期使用非甾体抗炎药及其他化学预防剂与后续结直肠肿瘤发生风险
Dig Dis Sci. 1996 Jul;41(7):1319-26. doi: 10.1007/BF02088554.